$RNN breakout candles $0.378 Above upper bollie
Post# of 16
Above upper bollie
Amex
Website
Last ten trades
10-K 2/24/17
100% x 100% Strong Buy
Shares Outstanding 237.44M
Float 230.21M
% Held by Insiders 4.19%
% Held by Institutions 4.80%
Shares Short 3 2.31M
Short Ratio 0.72
Short % of Float 1.12%
Shares Short (prior month) 2.84M
Stock technical analysis
news
and filings
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The companys clinical stage oncology candidates include Archexin that completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; RX-3117, which is in Phase Ib clinical trial for the treatment of patients with solid tumors; and Supinoxin that is in Phase I clinical trial for patients with solid tumors. It is also involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.